Author | Denise Myshko


Intracranial Responses Are Induced With Entrectinib in NTRK+ Tumors

September 20, 2020

Patients with NTRK fusion–positive solid tumors and baseline CNS metastases demonstrated durable intracranial activity with entrectinib, according to results of a small subpopulation analysis presented at the 2020 ESMO Virtual Congress.

Futibatinib Induces Durable Responses in FGFR2+ Intrahepatic Cholangiocarcinoma

September 18, 2020

Futibatinib demonstrated efficacy and tolerability when administered as treatment of patients with intrahepatic cholangiocarcinoma who harbor FGFR2 fusions/rearrangements, according to interim analysis results presented in a poster during the the European Society of Medical Oncology Virtual Congress 2020

Patients With AL Amyloidosis May Benefit From Subcutaneous Daratumumab/CyBorD Combination

August 20, 2020

Adding a subcutaneous formulation of daratumumab to the triplet regimen cyclophosphamide, bortezomib, and dexamethasone may hold promise for patients with newly diagnosed light chain amyloidosis who are in urgent need of new treatment options, according to a clinical trial.

Live, Virtual Events Take Center Stage for PER

August 03, 2020

In the face of canceled medical meetings this spring, continuing medical education offerings from Physicians’ Education Resource, LLC® were quickly transitioned from an in-person format to virtual presentations that have the ability to reach more medical specialists nationwide.